NASDAQ:DXCM - DexCom Stock Price, Forecast & News

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom, Inc. (NASDAQ:DXCM) announced its earnings results on Wednesday, November, 6th. The medical device company reported $0.65 EPS for the quarter, beating the Zacks' consensus estimate of $0.20 by $0.45. The medical device company earned $396.30 million during the quarter, compared to analysts' expectations of $348.99 million. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. The firm's revenue was up 48.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.17 earnings per share. View DexCom's Earnings History.

DexCom is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for DexCom.

DexCom will be holding an earnings conference call on Thursday, February 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

DexCom issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $457-457 million, compared to the consensus revenue estimate of $431.47 million.

15 Wall Street analysts have issued 12 month price targets for DexCom's stock. Their forecasts range from $125.00 to $255.00. On average, they expect DexCom's stock price to reach $207.43 in the next year. This suggests that the stock has a possible downside of 10.1%. View Analyst Price Targets for DexCom.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.

News articles about DXCM stock have been trending negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DexCom earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for DexCom.

Some companies that are related to DexCom include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Paypal (PYPL), Netflix (NFLX), Home Depot (HD), ServiceNow (NOW), Micron Technology (MU), Veeva Systems (VEEV) and Adobe (ADBE).

DexCom's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Chicago Capital LLC (0.21%), Peregrine Capital Management LLC (0.10%), Patten & Patten Inc. TN (0.02%), Johanson Financial Advisors Inc. (0.01%), Gateway Investment Advisers LLC (0.01%) and DNB Asset Management AS (0.01%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Tocqueville Asset Management L.P., Gateway Investment Advisers LLC, Chicago Capital LLC, Nisa Investment Advisors LLC, CenturyLink Investment Management Co, Patten & Patten Inc. TN and OLD National Bancorp IN. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman and Steven Robert Pacelli. View Insider Buying and Selling for DexCom.

DXCM stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., DNB Asset Management AS, Assenagon Asset Management S.A., HWG Holdings LP, IFM Investors Pty Ltd, Zeke Capital Advisors LLC, Huntington National Bank and BKD Wealth Advisors LLC. View Insider Buying and Selling for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $230.79.

DexCom has a market capitalization of $21.12 billion and generates $1.03 billion in revenue each year. The medical device company earns $-127,100,000.00 in net income (profit) each year or $0.30 on an earnings per share basis. DexCom employs 2,800 workers across the globe.View Additional Information About DexCom.

The official website for DexCom is http://www.dexcom.com/.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]